People with ‘hybrid immunity’ are strongest against re-infection with Omicron

The first study, published in the medical journal The Lancet Infection Diseasesanalyzed the data health of more than 200,000 people in 2020 and 2021 in Brazil, the country with the highest number of deaths from Covid-19 2nd largest world.

The results have found that, for people who have been infected with Covid-19, vaccination with Pfizer and AstraZeneca is 90% effective against hospitalization and death from re-infection with Covid-19, and Vero Cell injection is also 81% effective. , and Johnson & Johnson’s 1 shot is 58% effective, according to Hindustan Times.

People infected with Covid-19, then inject 3 doses of the strongest vaccine against Omicron re-infection, both BA.1 and BA.2 Shutterstock

Study author Dr Julio Croda, from the Federal University of Mato Grosso do Sul (Brazil), said: “All four of these vaccines have been shown to provide significant additional protection for people who have been infected with Covid-19 before”.

Dr Pramod Kumar Garg, from Translational Health Science and Technology Institute (India), said: “Hybrid immunity from Covid-19 infection and vaccination could be the global standard and can provide long-term protection. long-term resistance to reinfection including new variants”, according to Hindustan Times.

And the second study, using the Swedish national registry up to October 2021, showed people who had infected with Covid-19 remain highly resistant to reinfection for up to 20 months.

And people who were already infected with Covid-19, who received two doses of the vaccine, had a 66% lower risk of re-infection compared with not vaccinated.

And those who were already infected with Covid-19, who received two doses of the vaccine, had a 66% lower risk of re-infection compared to those who were not vaccinated. Shutterstock

People infected with Covid-19 and then injected with 3 doses of the vaccine that can fight against Omicron are the strongest

But Dr Paul Hunter, professor of medicine at the University of East Anglia (UK), warned that both studies were completed before Omicron variant dominated the world, and it “dramatically reduced the protection afforded by previous Covid-19 infection”.

Faced with this concern, a study in Qatar was published on the page pending approval medRxiv recently explored the possibility of hybrid immunity protection against Omicron in fully vaccinated and infected people with Covid-19.

The results found that three doses of the vaccine were 52% effective against severe infection caused by the BA.2 subvariant of Omicron, but this increased to 77% if the patient had had Covid-19 before. .

The study concluded that “hybrid immunity to Covid-19 infection prior to 3 doses of vaccine confers the strongest protection” against both Omicron’s BA.1 and BA.2 subvariates, according to Hindustan Times.